A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF

A PHASE 2B DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NON-VIRAL MEDIATED GENE THERAPY FOR CF

Bibliographic Details
Main Authors:	Alton, E, Boyd, A, Cheng, S, Cunningham, S, Davies, J, Gill, DR, Griesenbach, U, Higgins, T, Hyde, S, Innes, J, Porteous, D, Scheule, R, UC
Format:	Journal article
Published:	2013

Similar Items

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis.
by: Alton, E, et al.
Published: (2013)

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis
by: Alton, E, et al.
Published: (2013)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
by: Alton, E, et al.
Published: (2012)

UPDATE ON THE UK CF GENE THERAPY CONSORTIUM MULTIDOSE, NON-VIRAL, GENE THERAPY TRIAL
by: Alton, E, et al.
Published: (2012)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CF
by: Davies, J, et al.
Published: (2011)

Update on the UK CF Gene Therapy Consortium Multidoes, non-viral, gene therapy trial
by: Alton, E, et al.
Published: (2012)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
by: Davies, J, et al.
Published: (2009)

A randomized, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis
by: Alton, E, et al.
Published: (2015)

TOXICOLOGY STUDIES IN SUPPORT OF THE UK CF GENE THERAPY CONSORTIUM'S MULTI-DOSE CLINICAL TRIAL
by: Griesenbach, U, et al.
Published: (2011)

Genetic medicines for CF: Hype versus reality
by: Alton, E, et al.
Published: (2016)

EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CYSTIC FIBROSIS: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY''
by: Davies, J, et al.
Published: (2009)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
by: Davies, G, et al.
Published: (2011)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
by: Alton, E, et al.
Published: (2012)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS; THE RUN-IN STUDY
by: Alton, E, et al.
Published: (2010)

UKCF gene therapy consortium tracking study: Sputum and serum calprotectin are useful novel measurements in CF exacerbation
by: Gray, R, et al.
Published: (2007)

LONGITUDINAL ASSESSMENT OF BIOMARKERS FOR CLINICAL TRIALS OF NOVEL THERAPEUTIC AGENTS: THE RUN-IN STUDY
by: Alton, E, et al.
Published: (2010)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung.
by: Alton, E, et al.
Published: (2014)

Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung
by: Alton, E, et al.
Published: (2014)

REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
by: Alton, E, et al.
Published: (2012)

Production of SIV-F/HN: a new Lentivirus vector for CF gene therapy
by: Hyde, S, et al.
Published: (2015)

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
by: Alton, EWFW, et al.
Published: (2015)

Self-reactive CFTR T cells in humans: implications for gene therapy.
by: Calcedo, R, et al.
Published: (2013)

EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH CF: DATA FROM THE UK CF GENE THERAPY CONSORTIUM (UKCFGTC) 'RUN-IN' STUDY
by: Saunders, C, et al.
Published: (2010)

Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study
by: Lutz Nährlich, et al.
Published: (2013-04-01)

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis
by: Alton, EWFW, et al.
Published: (2016)

DEVELOPMENT, PRODUCTION AND EVALUATION OF CLINICAL GRADE CFTR EXPRESSION PLASMID FOR CF LUNG GENE THERAPY
by: Gill, DR, et al.
Published: (2010)

Moving lentiviral-based gene therapy into a first-in-man CF trial
by: Griesenbach, D, et al.
Published: (2015)

Pre-existing immunity to human parainfluenza virus (hPIV) does not affect rSIV.F/HN-mediated transduction efficiency
by: Pytel, K, et al.
Published: (2016)

Delivery of genes into the CF airway
by: Gill, D, et al.
Published: (2014)

Assessment of CFTR function after gene transfer in vitro and in vivo.
by: Griesenbach, U, et al.
Published: (2008)

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis
by: Eric WFW Alton, et al.
Published: (2016-07-01)

Towards a first-in-human trial with a pseudotyped lentivirus
by: Alton, EW, et al.
Published: (2020)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS IN A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
by: Griesenbach, U, et al.
Published: (2012)

Detection of CFTR transgene mRNA expression in respiratory epithelium isolated from the murine nasal cavity.
by: Holder, E, et al.
Published: (2010)

Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.
by: Griesenbach, U, et al.
Published: (2012)

ASSESSMENT OF F/HN-PSEUDOTYPED LENTIVIRUS AS A CLINICALLY RELEVANT VECTOR FOR LUNG GENE THERAPY
by: Griesenbach, U, et al.
Published: (2012)

Gene therapy for respiratory diseases; progress and a changing context
by: Alton, EWFW, et al.
Published: (2020)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep
by: Alton, E, et al.
Published: (2013)

The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep.
by: Alton, E, et al.
Published: (2013)

Preparation for a first-in-man lentivirus trial in cystic fibrosis patients
by: Griesenbach, U, et al.
Published: (2016)